Repare Therapeutics Inc (NASDAQ: RPTX) has experienced a decline in its stock price by -5.92 compared to its previous closing price of 3.21. However, the company has seen a fall of -22.56% in its stock price over the last five trading days. Business Wire reported 2024-02-29 that CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two upcoming investor conferences. Details for the presentations are as follows. TD Cowen 44th Annual Healthcare Conference Panel Discussion: Gynecological Cancers Date: Tuesday, March 5, 2024 Time: 10:30 a.m. Eastern Time Location: Boston, MA Bloom Bu.
Is It Worth Investing in Repare Therapeutics Inc (NASDAQ: RPTX) Right Now?
The 36-month beta value for RPTX is also noteworthy at 0.69. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for RPTX is 28.51M, and at present, short sellers hold a 2.39% of that float. The average trading volume of RPTX on April 19, 2024 was 127.28K shares.
RPTX’s Market Performance
The stock of Repare Therapeutics Inc (RPTX) has seen a -22.56% decrease in the past week, with a -42.37% drop in the past month, and a -50.65% fall in the past quarter. The volatility ratio for the week is 8.61%, and the volatility levels for the past 30 days are at 8.18% for RPTX. The simple moving average for the past 20 days is -28.57% for RPTX’s stock, with a -58.17% simple moving average for the past 200 days.
Analysts’ Opinion of RPTX
Many brokerage firms have already submitted their reports for RPTX stocks, with Stifel repeating the rating for RPTX by listing it as a “Buy.” The predicted price for RPTX in the upcoming period, according to Stifel is $16 based on the research report published on June 09, 2023 of the previous year 2023.
Morgan Stanley, on the other hand, stated in their research note that they expect to see RPTX reach a price target of $15, previously predicting the price at $28. The rating they have provided for RPTX stocks is “Equal-Weight” according to the report published on February 03rd, 2023.
CapitalOne gave a rating of “Overweight” to RPTX, setting the target price at $28 in the report published on January 06th of the previous year.
RPTX Trading at -45.90% from the 50-Day Moving Average
After a stumble in the market that brought RPTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.19% of loss for the given period.
Volatility was left at 8.18%, however, over the last 30 days, the volatility rate increased by 8.61%, as shares sank -42.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -62.20% lower at present.
During the last 5 trading sessions, RPTX fell by -22.56%, which changed the moving average for the period of 200-days by -71.29% in comparison to the 20-day moving average, which settled at $4.12. In addition, Repare Therapeutics Inc saw -58.63% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RPTX starting from Segal Lloyd Mitchell, who sale 2,491 shares at the price of $4.63 back on Apr 01 ’24. After this action, Segal Lloyd Mitchell now owns 107,558 shares of Repare Therapeutics Inc, valued at $11,533 using the latest closing price.
Forte Steve, the EVP, CHIEF FINANCIAL OFFICER of Repare Therapeutics Inc, sale 789 shares at $4.61 during a trade that took place back on Apr 01 ’24, which means that Forte Steve is holding 44,775 shares at $3,637 based on the most recent closing price.
Stock Fundamentals for RPTX
Current profitability levels for the company are sitting at:
- -2.26 for the present operating margin
- 0.93 for the gross margin
The net margin for Repare Therapeutics Inc stands at -1.83. The total capital return value is set at -0.54. Equity return is now at value -38.16, with -30.36 for asset returns.
Based on Repare Therapeutics Inc (RPTX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -37.29. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 30.96.
Currently, EBITDA for the company is -112.81 million with net debt to EBITDA at 0.94. When we switch over and look at the enterprise to sales, we see a ratio of 0.38. The receivables turnover for the company is 3.34for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.24.
Conclusion
In summary, Repare Therapeutics Inc (RPTX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
